ARO-ANG3 在纯合子家族性高胆固醇血症 (HOFH) 参与者中的研究 (Gateway)
2026年5月20日 更新者:Arrowhead Pharmaceuticals
评估 ARO-ANG3 在纯合子家族性高胆固醇血症 (HOFH) 受试者中的安全性和有效性的第 2 期研究
已提供知情同意书的记录在案的纯合子家族性高胆固醇血症 (HoFH) 的参与者将接受 2 次开放标签剂量的 ARO-ANG3,并在 36 周内评估安全性和有效性参数。
完成第一个 36 周治疗期的参与者可以选择继续额外的 24 个月延长期,在此期间他们将接受多达 8 剂开放标签剂量的 ARO-ANG3。
研究概览
研究类型
介入性
注册 (实际的)
18
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Quebec
-
Chicoutimi、Quebec、加拿大、G7H 7K9
- Research Site 2
-
Québec、Quebec、加拿大、G1V 4W2
- Research Site 1
-
-
-
-
-
Johannesburg、南非、2193
- Research Site 7
-
-
-
-
New South Wales
-
Camperdown、New South Wales、澳大利亚、2050
- Research Site 8
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- Research Site 3
-
-
-
-
New York
-
Mount Sinai、New York、美国、10029
- Research Site 4
-
-
Ohio
-
Cincinnati、Ohio、美国、45227
- Research Site 5
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
16年 及以上 (孩子、成人、年长者)
接受健康志愿者
不
描述
纳入标准:
- 筛选时空腹 LDL-C >100 mg/dL
- 体重≥40kg且体重指数≥18.5且≤40kg/m2
- 基于支持性基因检测或临床诊断的 HoFH 诊断
- 稳定的最大耐受降脂治疗
- 在第 1 天之前至少 4 周内愿意遵守稳定的低脂肪、低胆固醇、有益心脏健康的饮食
- 有生育潜力的参与者(男性和女性)必须同意在研究期间以及从最后一剂研究药物起至少 24 周内使用高效避孕措施。
- 有生育能力的妇女必须进行阴性妊娠试验并且不能进行母乳喂养
- 使用激素避孕药的育龄妇女在第 1 天之前必须稳定服用 > 2 个月经周期
- 愿意提供书面知情同意书并遵守研究要求
排除标准:
- 当前使用或从第 1 天起 365 天内使用任何肝细胞靶向小干扰 RNA 寡核苷酸 (siRNA) 或反义寡核苷分子
- 使用 evinacumab(一些例外情况适用)
- 筛选时空腹 TG > 300 mg/dL
- 存在任何已知影响血清脂质或脂蛋白的临床显着的不受控制的内分泌疾病
- 新诊断(知情同意前 3 个月内)或控制不佳的糖尿病(血红蛋白 A1c > 9%)
- 使用全身性皮质类固醇(一些例外情况适用)
- 心肌缺血或严重左心室功能不全的症状
- 第 1 天后 3 年内的转移性恶性肿瘤病史(某些例外情况适用)
- 计划的心脏手术/手术,例如冠状动脉旁路移植术 (CABG) 手术、经皮冠状动脉介入治疗 (PCI)、颈动脉手术或支架置入术,或颈动脉血运重建术
注意:额外的包含/排除标准可能适用于每个协议
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ARO-ANG3 剂量 1
ARO-ANG3 剂量水平 1 皮下 (SC)
|
参与者将在研究的最初 36 周的第 1 天和第 84 天以及延长期的第 1 天和第 3、6、9、12、15、18 和 21 个月随机接受 ARO-ANG3 SC
|
|
实验性的:ARO-ANG3 剂量 2
ARO-ANG3 剂量水平 2 SC
|
参与者将在研究的最初 36 周的第 1 天和第 84 天以及延长期的第 1 天和第 3、6、9、12、15、18 和 21 个月随机接受 ARO-ANG3 SC
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Percent Change From Baseline in Fasting LDL-C at Week 24
大体时间:Baseline, Week 24
|
LDL-C, computed using Friedewald formula, Martin-Hopkins methodology and preparative ultracentrifugation (PUC).
|
Baseline, Week 24
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
大体时间:From first dose of study drug up to Week 36 (initial treatment period), and up to Month 24 (extension period)
|
An adverse event (AE) is any untoward medical occurrence, which does not necessarily have to have a causal relationship with this treatment.
A serious adverse event (SAE) is an AE occurring during any study phase that: results in death; is immediately life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability or incapacity; results in a congenital abnormality or birth defect; is an important medically important event or reaction that may require medical intervention to prevent one of the outcomes listed above.
AEs are considered treatment-related if the relationship to the study drug is 'possibly related', 'probably related'.
A TEAE is defined as an AE that occurs following IP administration or a pre-existing condition exacerbated following IP administration.
Injection site reactions are assessed at every visit starting on Day 1 and include any Preferred Term containing 'Injection Site'.
|
From first dose of study drug up to Week 36 (initial treatment period), and up to Month 24 (extension period)
|
|
Percentage of Participants Meeting United States National Lipid Association Apheresis Eligibility Criteria of LDL-C ≥ 300 mg/dL at Week 24
大体时间:Week 24
|
Apheresis is the extracorporeal process of removing one or more blood constituents from whole blood and returning the remainder to the circulation.The National Lipid Association outlines eligibility criteria for apheresis, particularly for patients with familial hypercholesterolemia who have not achieved target LDL cholesterol levels despite maximally tolerated pharmacotherapy.
LDL-C ≥ 300 mg/dL is a criterion.
|
Week 24
|
|
Percentage of Participants Meeting European Union (EU) Apheresis Eligibility Criteria Per German Apheresis Working Group at Week 24
大体时间:Week 24
|
Apheresis is the extracorporeal process of removing one or more blood constituents from whole blood and returning the remainder to the circulation. The European Union (EU) apheresis eligibility criteria (per German Apheresis Working Group) include the following categories:
|
Week 24
|
|
Percent Change From Baseline in Fasting LDL-C (PUC) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting LDL-C (PUC) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Calculated LDL-C (Friedewald Formula) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting Calculated LDL-C (Friedewald Formula) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Calculated LDL-C (Martin-Hopkins Methodology) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting Calculated LDL-C (Martin-Hopkins Methodology) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Angiopoietin-like 3 (ANGPTL3) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting ANGPTL3 Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Total Apolipoprotein B (ApoB) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting Total ApoB Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting HDL-C Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Non-HDL-C Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting Non-HDL-C Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Very-Low-Density Lipoprotein-Cholesterol (VLDL-C) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting VLDL-C Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Total Cholesterol (TC) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting TC Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Percent Change From Baseline in Fasting Triglycerides (TG) Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Absolute Change From Baseline in Fasting TG Over Time
大体时间:Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36 (Day 1 of Extension Period), Extension Months 1, 2, 3, 6, 9, 12, 15, 18, 21
|
|
|
Number of Participants With Anti-Drug Antibodies (ADAs) to ARO-ANG3 Over Time
大体时间:Baseline, Day 1, Weeks 4, 12, 16, 24 (initial treatment period), Week 36/Day 1, Months 1, 3, 6, 9, 12, 15, 18, 21 (extension period)
|
Baseline, Day 1, Weeks 4, 12, 16, 24 (initial treatment period), Week 36/Day 1, Months 1, 3, 6, 9, 12, 15, 18, 21 (extension period)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Dimitriadis K, Theofilis P, Iliakis P, Pyrpyris N, Dri E, Sakalidis A, Soulaidopoulos S, Tsioufis P, Fragkoulis C, Chrysohoou C, Tsiachris D, Tsioufis K. Management of dyslipidemia in coronary artery disease: the present and the future. Coron Artery Dis. 2024 Sep 1;35(6):516-524. doi: 10.1097/MCA.0000000000001375. Epub 2024 Apr 29.
- Raal FJ, Bergeron J, Gaudet D, Rosenson RS, Sullivan DR, Turner T, Hegele RA, Ballantyne CM, Knowles JW, Leeper NJ, Goldberg IJ, Zhou R, Muhsin M, Hellawell J, Hamilton J, Watts GF. Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2026 Feb;14(2):123-136. doi: 10.1016/S2213-8587(25)00290-6. Epub 2025 Dec 18.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2022年4月22日
初级完成 (实际的)
2023年5月2日
研究完成 (实际的)
2025年11月13日
研究注册日期
首次提交
2022年1月20日
首先提交符合 QC 标准的
2022年1月20日
首次发布 (实际的)
2022年2月1日
研究记录更新
最后更新发布 (实际的)
2026年6月12日
上次提交的符合 QC 标准的更新
2026年5月20日
最后验证
2026年5月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- AROANG3-2003
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
不
药物和器械信息、研究文件
研究美国 FDA 监管的药品
是的
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.